AWY0
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia. The company's lead asset is ATL1102, an antisense oligonucleotide inhibitor of CD49d, which is in Phase IIb clinical trial for the treatment of Duchenne muscular dystrophy, multiple sclerosis, asthma, and other inflammatory indications. It also devel… Read more
AWY0 (AWY0) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, AWY0 (AWY0) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
AWY0 - Net Assets Trend (None–None)
This chart illustrates how AWY0's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for AWY0 (None–None)
The table below shows the annual net assets of AWY0 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to AWY0's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
AWY0 Competitors by Market Cap
The table below lists competitors of AWY0 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jakpaisan Estate Public Company Limited
BK:JAK
|
$2.00 Million |
|
TOMCO ENERGY POST CON.
F:NI41
|
$2.00 Million |
|
SCUT SA BACAU
RO:SCBC
|
$2.00 Million |
|
Everything Blockchain Inc.
PINK:EBZT
|
$2.00 Million |
|
Edison Lithium Corp
V:EDDY
|
$2.00 Million |
|
Nagreeka Exports Limited
NSE:NAGREEKEXP
|
$2.00 Million |
|
SACCHERIA F.LLI FRANCES.
F:YV1
|
$2.00 Million |
|
Intersport Polska S.A.
WAR:IPO
|
$2.00 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AWY0's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares AWY0's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently AWY0 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares AWY0's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AWY0 (AWY0) | €- | N/A | N/A | $2.00 Million |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $243.78K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.26K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $987.66 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $77.40 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $35.57 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.73 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |